Recursion Pharmaceuticals Inc (RXRX) Directors and Executive Officers

Officers & Directors

Christopher Gibson
Chief Executive Officer and Director (Principal Executive Officer)

Dean Li
Director

Blake Borgeson
Director

R. Martin Chavez
Chair of the Board

Robert Hershberg
Director

Zachary Bogue
Director

Terry-Ann Burrell
Director

Zavain Dar
Director

Michael Secora
Chief Financial Officer (Principal Financial and Accounting Officer)

Christopher Gibson
Chief Executive Officer (Power of Attorney) ,

Recursion Pharmaceuticals Inc currently has 600 employees.

News about Recursion Pharmaceuticals Inc Key Personnel

Recursion Pharmaceuticals Advances Drug Discovery and Foundation Models with New Technology Releases and Strategic Partnerships

Advancements in Drug Discovery and Microscopy Data: Recursion Pharmaceuticals Sets New StandardsIn an era where innovation and technological advancements are vital to the pharmaceutical industry, Recursion Pharmaceuticals continues to make significant strides that are redefining drug discovery and expanding the capabilities of foundational models. Recently, the company announced the release of OpenPhenom-S/16 in Google Cloud’s Model Garden, a revolutionary foundation model built on microscopy data, which has outperformed existing benchmarks such as CellProfiler. This achievement marks a pivotal shift in how computational biology intersects with drug development, further underscoring Recursion s position a...

Recursion Pharmaceuticals Unveils Key Clinical Readouts and Partnership Updates at Download Day as It Aims to Overcome Financial Setbacks

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
Recursion, a leading clinical stage TechBio company focused on decoding biology to industrialize drug discovery, is set to provide updated pipeline guidance to investors, analysts, and other stakeholders during their latest event, Download Day, on Monday, June 24, 2024. Despite recording a cumulative net loss of $-354 million in the first quarter of 2024, resulting in a negative return on investment (ROI) of -66.38%, Recursion Pharmaceuticals Inc aims to showcase its progress and potential during the event.
Despite the financial challenges faced by Recursion Pharmaceuticals, the compan...